METHODS: In this case, a 28-year-old female patient presented with a 15-day history of fever and skin rash accompanied by sore throat, fatigue, myalgia, and arthralgia. Additionally, leucocytosis, aminotransferase abnormalities, and elevated inflammatory factor levels were observed. Infectious diseases, solid tumors, and hematological disorders were all ruled out. Anti-infective treatments proved ineffective, leading to the final diagnosis of AOSD. Glucocorticoid therapy provided only partial relief. Consequently, formulated ZYSGD and hepatoprotective drugs were added to the glucocorticoid treatment. Subsequently, the patient\'s symptoms and inflammatory biomarkers showed improvement. After discharge, the patient\'s condition remained stable while continuing the formulated ZYSGD in combination with 4 mg of Medrolol (qd) during a 10-month follow-up period.
CONCLUSIONS: This case report suggests that formulated ZYSGD could be a viable option for complementary and alternative therapy for late-stage AOSD, especially in cases involving both Qi and body fluid imbalances.
方法:在这种情况下,一名28岁的女性患者,有15天的发烧和皮疹史,并伴有喉咙痛,疲劳,肌痛,和关节痛.此外,白细胞增多症,转氨酶异常,观察到炎症因子水平升高。传染病,实体瘤,血液病都被排除了.抗感染治疗被证明是无效的,导致AOSD的最终诊断。糖皮质激素治疗仅部分缓解。因此,在糖皮质激素治疗中加入配方ZYSGD和保肝药物。随后,患者的症状和炎症生物标志物显示改善。放电后,在10个月的随访期间,患者的病情保持稳定,同时继续使用配制的ZYSGD与4mgMedrolol(qd)联用。
结论:该病例报告表明,配制的ZYSGD可能是晚期AOSD的补充和替代疗法的可行选择,尤其是在涉及气血和体液失衡的情况下。